Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Taps Invitrogen Alumnus as CCO; NCRR Names New Director; Archemix, BioTrove, and Alnylam Flesh Out Boards; and Others

An earlier version of this installment incorrectly reported that Caliper hired John DelliSanti to the posts of executive vice president and chief operating officer. In fact, he was hired as executive vice president and chief commercial officer.
NEW YORK (GenomeWeb News) — Caliper Life Sciences has named John DelliSanti to the posts of executive vice president and chief commercial officer. In the job, DelliSanti will oversee the company’s worldwide sales, marketing, and services functions.
DelliSanti previously led Invitrogen’s American commercial operations, worked in international sales and services at Accelrys for a dozen years, and worked for Wyeth Pharmaceuticals and Hitachi Instruments.

Barbara Alving has been named director of the National Center for Research Resources, part of the National Institutes of Health, the NIH said today. 
Alving has been serving as the NCRR’s acting director since 2005, but NIH Director Elias Zerhouni has now officially appointed her to the position.
Alving has worked as a public health officer for the US Food and Drug Administration on the NIH campus, has been the chief of the Department of Hematology and Vascular Biology at Walter Reed Army Institute of Research, was chief of the Department of Hematology and Oncology at the Washington Hospital Center and was a director of the Division of Blood Diseases and Resources at the National Heart, Lung, and Blood Institute.
She also is a professor of Medicine at the Uniformed Services University of Health Sciences, and has been a member of various committees on hematology

BioTrove has appointed Gregory Critchfield to its board of directors, the company said this week.
Critchfield, who is taking the seventh seat on Biotrove’s board, currently is president of Myriad Genetic Laboratories.
Critchfield also has been senior vice president, chief medical officer, and chief scientific officer at Quest Diagnostics.  

Cognia said this week that Ovid founder and CEO Mark Nelson has joined the
company as an advisor investor.
Cognia is a scientific database and aggregation company for pharmaceutical and biotech research.

Vicki Nienaber has taken the chief scientific officer post at ActiveSight, the company said this week. 
Nienaber recently was a senior director of lead discovery and crystallography at SGX Pharmaceuticals. She also worked at Abbott Laboratories, where she helped invent fragment-based screening and crystal sample-handling techniques.

Pharsight said this week it has promoted Dan Weiner to chief technology officer, and has named Dana Cambra to vice president of R&D.
Weiner has worked in biostatistics at Merrell Dow Pharmaceuticals and was vice president and scientist at Statistical Consultants, Syntex Development Research, Quintiles, IVAX Research.
Cambra previously was vice president of engineering at Stentor, and held similar positions at Visto, iScribe. He also was involved in software development at General Electric and Acuson.

Alnylam has elected Victor Dzau to its board of directors, the company said this week.
Dzau works at Duke University as president and CEO of the Duke University Health System, and as chancellor of Health Affairs. He also serves as a professor of medicine and as a director of Molecular and Genomic Vascular Biology at Duke.
Dzau previously was a professor of medicine at Harvard Medical School, and was chairman of the Department of Medicine at Brigham and Women’s Hospital.

Robert Schnabel will take over as dean of Indiana University’s School of Informatics, once his posting is approved by the university’s trustees, IU said this week.
Schnabel will replace Michael Dunn, who founded the IU informatics school and who plans to retire from the position at the end of June.
Schabel currently is vice provost/associate chancellor for Academic and Campus Technology at the University of Colorado at Boulder, where he also serves as chief information officer and as director of the Alliance for Technology, Learning and Society Institute.

Robert Stein has been appointed to the Archemix’s board of directors, the company said this week.
Stein previously has been president of Roche Palo Alto, and was president and CSO of Incyte. He also has held posts at Merck, Ligand Pharmaceuticals, and DuPont Merck Pharmaceutical company.

Samuel Mitchell, a senior scientist at an agriculture and biotechnology facility in Belfast, Northern Ireland, has won an HPLC system and a TOF LC mass spectrometer through an Agilent Technologies European sweepstakes, Agilent said this week.
Mitchell, of the Agri-Food & Biosciences Institute, won a 1200 Series liquid chromatography system and a 6510 Quadrupole Time-of-Flight LC/mass spectrometer, Agilent said. The company valued Mitchell’s winnings at $525,000. 
Mitchell said the new technology “will enhance [the institute’s] technical capabilities thus helping us with future funding applications.”

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.